Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01789242 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase 1 study, sponsored by Criterium.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01789242: Completed Phase 1 study, sponsored by Criterium.
NCT01789242 is a Phase 1 study that has completed, run by Criterium. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01789242, a Phase 1 study, has completed, sponsored by Criterium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a dose finding study to evaluate the safety and determine the maximum tolerated dose of carfilzomib in patients with previously treated systemic light-chain amyloidosis.
Primary Outcome
Review of adverse events for safety and to determine the maximum tolerated dose of the combination treatment
Interventions
- DRUG Dexamethasone
- DRUG Carfilzomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2013-02 |
| Est. Completion | 2017-07 |
| Phase | Phase 1 |
What the finished NCT01789242 record still lists
NCT01789242 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT01789242 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01789242 about?
NCT01789242 is a clinical study titled "A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis". This is a dose finding study to evaluate the safety and determine the maximum tolerated dose of carfilzomib in patients with previously treated systemic light-chain amyloidosis.
What is the current status of trial NCT01789242?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2013-02. Estimated completion is 2017-07.
What interventions are being tested in trial NCT01789242?
The interventions under investigation include: Dexamethasone (DRUG), Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT01789242?
This trial is sponsored by Criterium, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01789242's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia